A new group is seeking to warn European policymakers about AI’s ‘existential’ threat to humanity.
An Australian/German company is developing powerful quantum accelerators the size of graphics cards. They work at room temperature, undercutting and outperforming today’s huge, cryo-cooled quantum supercomputers, and soon they’ll be small enough for mobile devices.
A future with human brain-chip interfaces is not very far as Samsung has a published a Perspective paper titled “Neuromorphic electronics based on copying and pasting the brain”, which talks about a new way to copy th…
Now that we know that interstellar objects (ISOs) visit our Solar System, scientists are keen to understand them better. How could they be captured? If they’re captured, what happens to them? How many of them might be in our Solar System?
One team of researchers is trying to find answers.
Continue reading “What Happens to Interstellar Objects Captured by the Solar System?” »
Chipmakers are still catching up to demand following severe supply chain bottlenecks created by the pandemic. But manufacturing plants that were planned last year will likely start producing chips in the coming months, helping to alleviate shortages for PC parts and other microchips, Su said.
“We’ve always gone through cycles of ups and downs, where demand has exceeded supply, or vice versa,” Su said at the Code Conference in Beverly Hills, California. “This time, it’s different.”
The improvements will be gradual as more manufacturing capacity becomes available, Su said.
An inexpensive anti-seizure medication markedly improves learning and memory and other cognitive functions in Alzheimer’s patients who have epileptic activity in their brains, according to a study published in the Sept. 27th issue of JAMA Neurology.
“This is a drug that’s used for epilepsy,” says Keith Vossel, MD, MSc, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and the principal investigator on the clinical trial. “We used it in this study for Alzheimer’s patients who had evidence of silent epileptic activity, which is seizure-like brain activity without the associated physical convulsions.”
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Early symptoms include short-term memory loss, decline in problem solving, word-finding difficulties, and trouble with spatial navigation. Among Alzheimer’s patients, an estimated 10–22% develop seizures, while an additional 22–54% exhibit silent epileptic activity.
A large, UK-based study of genetics and autism spectrum disorder (ASD) has been suspended, following criticism that it failed to properly consult the autism community about the goals of the research. Concerns about the study include fears that its data could potentially be misused by other researchers seeking to ‘cure’ or eradicate ASD.
Study aimed at collecting DNA from 10,000 people with autism and their families has drawn criticism for failing to consult the autism community.
